Home | Medical-Newswire.Com:
(Medical-NewsWire.com, January 13, 2018 ) According to the report North America Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market published by the Market Data Forecast, The Market is expected to reach USD 3.98 billion by 2020 from USD 2.81 billion in 2015, growing at a CAGR of 7.20% during the forecast period 2015-2020.
Get a comprehensive overview of the North America ADHD Therapeutics Market: http://www.marketdataforecast.com/market-reports/north-america-attention-deficit-hyperactivity-disorder-therapeutics-market-305/
For Free Sample Report @ http://www.marketdataforecast.com/market-reports/north-america-attention-deficit-hyperactivity-disorder-therapeutics-market-305/request-sample
North America Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market: Segmentation
By Medication Type
Cognitive Behavioral Therapy
By Education or Training
Parent management training
Social skills training
By Geographical Analysis:
Avail Discount @ http://www.marketdataforecast.com/market-reports/north-america-attention-deficit-hyperactivity-disorder-therapeutics-market-305/request-discount
Attention deficit hyperactivity disorder (ADHD), is one of the most common neurological/psychiatric disorders among children and adolescents. ADHD is commonly observed in children (above 12 years age) as compared to adolescents. ADHD is also described as hyperkinetic disorder/ attention deficit disorder or neuropsychiatric disorder. The exact cause for the ADHD is not clear but, expected to be resulted due to genetic factors and environmental influences. ADHD results in improper functioning of nervous system that led to attention deficit and hyperactivity/impulsiveness condition. ADHD is characterized by certain symptoms include easy distraction & striving to maintain focus on one task, unable to remember things, impatience, and being continuously in motion, among others. The symptoms of attention deficit hyperactivity disorder (ADHD) are controlled by different modalities such as medication (stimulants-amphetamines; non-stimulants-atomoxetine), psychotherapy (behavior therapy, cognitive behavioral therapy), and education/training (parent management training, family training).
Reasons to buy North America Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report:
Regional and country-level analysis and forecasts of the study market; providing Insights on the geographical areas in which this industry is prospering
Segment-level analysis on basis of product type, application, color along with market size forecasts and y-o-y estimations to detect key areas of industry growth in detail
Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
Study of macro and micro environmental factors that affect the market presented in an extensive strategic analyses section containing PESTLE and Porters Five Forces Analyses
A comprehensive listing of key market players along with company overview, product portfolios, key financial information (subjected to availability), SWOT analysis and Analyst overview to study and sustain the market environment
Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
Expertly devised Market Outlook along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
Availability of good healthcare infrastructure, presence of ongoing clinical trials, early approval of therapeutics in the U.S., increasing number of learning disability patients, growing adoption for ADHD therapeutics, existence of insurance policies for brain monitoring technologies, and government support for the technological advancements in neurosciences are driving the growth of attention deficit hyperactivity disorder therapeutics market in North America. However, stringent government regulations for the approval of neurological therapeutics and cost pertaining to the ADHD medication are restraining the growth of attention deficit hyperactivity disorder therapeutics market in North America.
Buy now @ https://www.marketdataforecast.com/cart/buy-now/north-america-attention-deficit-hyperactivity-disorder-therapeutics-market-305
U.S., accounted for larger share of the North America attention deficit hyperactivity disorder (ADHD) therapeutics market in 2015, whereas Canada is estimated to grow at a higher CAGR during the forecast period 2015-2020.
The key players in attention deficit hyperactivity disorder (ADHD) therapeutics market such as, Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.), and Curemark, LLC. (U.S.).
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
Market Data Forecast